Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · OnKure Therapeutics, Inc. (OKUR)

OnKure Therapeutics Q3 net loss widens to $17.8 million from $14.7 million

Mixed Impact 3 of 5 earnings Written later

OnKure Therapeutics reported third quarter 2026 results with a net loss of $17.8 million, or $0.36 per share, compared with $14.7 million, or $1.09 per share, a year earlier. The dollar loss grew as research and development and general and administrative expenses rose, while the per-share loss narrowed on a much larger weighted share count of 49.9 million versus 13.5 million. The company reported $163.3 million in cash, cash equivalents and marketable securities as of September 30, 2026, and said this is expected to fund operations into 2029.

Key points

  • Q3 2026 net loss was $17.8 million ($0.36 per share), up from $14.7 million ($1.09 per share) in Q3 2025
  • R&D expenses were $15.1 million, up from $11.9 million; G&A expenses were $4.3 million, up from $3.6 million
  • Cash, cash equivalents and marketable securities were $163.3 million at September 30, 2026, expected to provide runway into 2029
  • IND submissions for OKI-355 (vascular anomalies) and OKI-345 (breast cancer) are planned for the first half of 2027

The filing

CompanyOnKure Therapeutics, Inc. (OKUR)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:10 PM ET
Accession number0001193125-26-447247

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.